• Masaya Baba, Jonathan R Keller, Hong-Wei Sun, Wolfgang Resch, Stefan Kuchen, Hyung Chan Suh, Hisashi Hasumi, Yukiko Hasumi, Kyong-Rim Kieffer-Kwon, Carme Gallego Gonzalez, Robert M Hughes, Mara E Klein, Hyoungbin F Oh, Paul Bible, Eileen Southon, Lino Tessarollo, Laura S Schmidt, W Marston Linehan, and Rafael Casellas.
• Urologic Oncology Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
• Blood. 2012 Aug 9; 120 (6): 1254-61.

AbstractBirt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder characterized by cutaneous fibrofolliculomas, pulmonary cysts, and kidney malignancies. Affected individuals carry germ line mutations in folliculin (FLCN), a tumor suppressor gene that becomes biallelically inactivated in kidney tumors by second-hit mutations. Similar to other factors implicated in kidney cancer, FLCN has been shown to modulate activation of mammalian target of rapamycin (mTOR). However, its precise in vivo function is largely unknown because germ line deletion of Flcn results in early embryonic lethality in animal models. Here, we describe mice deficient in the newly characterized folliculin-interacting protein 1 (Fnip1). In contrast to Flcn, Fnip1(-/-) mice develop normally, are not susceptible to kidney neoplasia, but display a striking pro-B cell block that is entirely independent of mTOR activity. We show that this developmental arrest results from rapid caspase-induced pre-B cell death, and that a Bcl2 transgene reconstitutes mature B-cell populations, respectively. We also demonstrate that conditional deletion of Flcn recapitulates the pro-B cell arrest of Fnip1(-/-) mice. Our studies thus demonstrate that the FLCN-FNIP complex deregulated in BHD syndrome is absolutely required for B-cell differentiation, and that it functions through both mTOR-dependent and independent pathways.

33 keywords...

hide…